Lilly describe la perspectiva de ingresos de $91B-$92B para 2026 a medida que el puente GLP-1 del Medicare y el despliegue de Foundayo expanden el acceso

Resumen del corpus

Eli Lilly describes revenue prospects of $91B-$92B for 2026, driven by the GLP-1 bridge for Medicare and the deployment of Foundayo, which expands access to treatments. The company reported solid financial results, raised its full-year financial guidance, advanced its pipeline, and expanded its manufacturing footprint, according to President and CEO David Ricks.